Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AXAL

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

Merck granted FDA approval for Keytruda combination in cervical cancer

The decision marks the third FDA-approved indication for Keytruda in cervical cancer

- PMLiVE

UCL study finds use of existing drugs improves cervical cancer outcomes

The approach was shown to reduce the risk of death or cancer recurrence by 35%

- PMLiVE

Seagen and Genmab’s Tivdak shows promise in phase 3 cervical cancer trial

The drug received FDA accelerated approval in 2021 to treat patients with advanced disease

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

regeneron headquarters

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

A phase 3 trial demonstrated a 31% reduction in the risk of death compared to chemotherapy

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

WHO/Europe urges endorsement of cervical cancer elimination roadmap

The initiative aims to fully vaccinate 90% of girls with the HPV vaccine by age 15

- PMLiVE

Cervical Cancer Prevention Month

In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer

Innovative Trials

- PMLiVE

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

The drug has been granted accelerated approval, and the companies have also released positive data on first-line treatment

- PMLiVE

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links